Fri Sep 20 08:46:50 UTC 2024: ## Apellis Pharmaceuticals Director Sells Shares, Institutional Investors Active
**New York, NY** – A. Sinclair Dunlop, Director of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS), sold 37,000 shares of the company’s stock on September 16th, according to a recent SEC filing. The transaction totaled $1,340,510.00, with Dunlop now holding 100,000 shares valued at $3,623,000.
Meanwhile, institutional investors continue to show interest in Apellis Pharmaceuticals. Norges Bank acquired a new position in the company valued at $56,640,000 in the fourth quarter, while Mirae Asset Global Investments Co. Ltd. invested $3,218,000 in the first quarter. Bellevue Group AG increased its stake by 3.5% in the fourth quarter, now holding 821,800 shares worth $49,193,000. Other notable institutional investors include Edgestream Partners L.P. and Altitude Crest Partners Inc.
Analysts remain divided on the company’s prospects. Wells Fargo & Company lowered its price target to $48.00 from $57.00, while HC Wainwright cut its target from $92.00 to $83.00. However, Goldman Sachs Group raised its price objective from $66.00 to $74.00. Wedbush increased its price objective from $38.00 to $41.00 and maintained a “neutral” rating. Overall, the stock has an average rating of “Moderate Buy” with a price target of $71.67.
Apellis Pharmaceuticals develops and commercializes therapeutic compounds to treat autoimmune and inflammatory diseases. The company markets EMPAVELI for paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and other conditions, and SYFOVRE for age-related macular degeneration.
**Disclaimer:** This news article is intended for informational purposes only and does not constitute financial advice. Investors are encouraged to conduct their own research and consult with a financial professional before making any investment decisions.
First Piper 